Primary outcome
microvascular obstruction, Pre-PCI, Troponin-T, intramyocardial hemorrhage, ventricular tachycardia/ventricular fibrillation, IMH, TIMI, inflammation, MVO, myocardial Infarction, heart failure, infarct
ADVERSE EVENTS, INFLAMMATION, HEART FAILURE, INFARCT
Final infarct size (% of left ventricle (LV) mass) measured by LGE on CMR 3 months following STEMI.Secondary outcomes.CMR efficacy outcomes:The extent of microvascular obstruction (MVO) on acute and follow-up CMRPresence of intramyocardial hemorrhage (IMH) on acute CMRAcute and persistent MVO on acute and follow-up CMR (yes/no)Area at risk (AAR) on acute CMR (%LV)Acute infarct size (%LV)Myocardial salvage index (MSI) on acute and follow-up CMR (%)LVEF on acute and follow-up CMR (%)All-cause mortality and hospitalization for heart failure at 3 monthsPeak Troponin-T and creatine kinase (CK)/CKMB during admissionIncidence of adverse events the first seven days of the index eventExploratory outcomes.Pre-PCI and post-PCI thrombolysis in myocardial Infarction (TIMI) flowC-reactive protein (CRP), leucocyte and differential count, thrombocytes, HbA1c, p-glucose, pro-brain natriuretic peptide (BNP), creatine kinase, creatinine, potassium, and sodium at admission, during admission, and after 3 monthsArrhythmia (ventricular tachycardia/ventricular fibrillation) leading to cardioversion from inclusion to hospital dischargeKillip class at admissionCoronary flow reserve (CFR) and index of microvascular resistance (IMR) following primary PCILVEF on transthoracic echocardiography during admission and at one to 3 monthsBiomarkers of inflammation at admission, 24 h after admission, and after 3 monthsLV mass, LV end-diastolic-volume index, LV end-systolic-volume index, and LV remodeling (change in LV-volume index) on CMR at 3 monthsAll-cause mortality and hospitalization for HF after 1 and 10 years